0
0
MUMBAI — In a landmark development for the treatment of neurodegenerative diseases in South Asia, Eli Lilly and Company officially launched donanemab in India on May 13, 2026. Marketed under the brand name Lormalzi, the drug represents the first disease-modifying therapy for Alzheimer’s disease to reach the Indian market following authorization from the Central Drugs Standard Control Organization (CDSCO).
The intravenous (IV) monoclonal antibody therapy is indicated specifically for adults in the early symptomatic stages of the disease, including those with mild cognitive impairment (MCI) or mild dementia. While the medical community has hailed the launch as a scientific milestone, the treatment’s debut has immediately sparked a national conversation regarding its price point—set at ₹91,688 per 350 mg vial—and the complex infrastructure required to administer it safely.
A New Frontier: Targeting the Root of the Disease
Unlike traditional Alzheimer’s treatments such as cholinesterase inhibitors, which temporarily manage symptoms like memory loss and confusion, donanemab is designed to alter the course of the disease itself.
The therapy works by identifying and clearing amyloid-beta plaques—toxic protein clusters that accumulate in the brains of Alzheimer’s patients and are believed to drive cognitive decline. By removing these plaques, the drug aims to provide patients with more time in the earlier, more independent stages of the illness.
According to global Phase 3 clinical trial data, donanemab significantly slowed clinical decline in patients with early symptomatic Alzheimer’s. The medication is administered via an IV infusion once every four weeks. Notably, the treatment protocol allows for the possibility of stopping infusions once a patient’s plaque levels drop below a certain threshold, a “finite dosing” approach that distinguishes it from other biologics in its class.
The Cost of Innovation
The launch price of ₹91,688 (approximately $957) per vial places Lormalzi among the most expensive outpatient therapies in India. Given that dosage is weight-based and typically requires multiple vials per monthly infusion, the annual cost for a single patient could reach several lakhs of rupees.
Winselow Tucker, President and General Manager of Eli Lilly and Company (India), stated in industry reports that the pricing reflects the “clinical value” the drug provides in slowing a devastating disease. However, public health experts warn that without robust insurance coverage or government subsidies, the drug may remain out of reach for the vast majority of India’s aging population.
Expert Perspectives: “Proceed with Cautious Optimism”
While the pharmaceutical industry celebrates the launch, independent neurologists are emphasizing the need for rigorous patient selection.
“This is a significant step forward, but it is not a ‘cure’ for all forms of dementia,” notes one dementia specialist in recent clinical briefings. “The benefits observed in trials are modest and are strictly confined to those in the very early stages of the disease who have confirmed amyloid pathology.”
Safety and Monitoring (ARIA)
Beyond cost, the primary concern for clinicians is a side effect known as ARIA (Amyloid-Related Imaging Abnormalities). This condition involves temporary swelling in areas of the brain or small spots of bleeding. While often asymptomatic, ARIA can be serious if not managed.
To ensure patient safety, the CDSCO and medical societies recommend:
-
Mandatory Baseline Testing: Confirmation of amyloid plaques via PET scans or cerebrospinal fluid (CSF) testing before starting therapy.
-
Routine MRI Monitoring: Regular brain scans during the treatment course to detect and manage potential ARIA.
-
Specialized Centers: Administration should only occur in facilities equipped with advanced imaging and neurologists trained in identifying monoclonal antibody complications.
The Indian Context: Challenges and Opportunities
The arrival of donanemab comes at a time of rising dementia prevalence in India. While the CDSCO authorized the drug based on global data, the lack of India-specific efficacy trials has drawn some scrutiny. In response, Eli Lilly is expected to conduct post-marketing surveillance and Phase IV studies to monitor the drug’s performance specifically within the Indian demographic.
The Access Gap
Public health advocates point to a brewing “urban-rural divide.” The requirement for high-tech diagnostics like PET scans and specialized MRI protocols means that Lormalzi will likely be restricted to Tier-1 cities and premium private hospitals. For patients in rural or semi-urban areas, accessing the drug—and the necessary safety monitoring—remains a formidable hurdle.
What This Means for Patients and Caregivers
For families navigating an Alzheimer’s diagnosis, the availability of Lormalzi offers a new, though complex, option. If you or a loved one are considering this therapy, here is the typical clinical pathway:
-
Diagnostic Evaluation: A comprehensive workup by a neurologist to determine if cognitive changes are due to Alzheimer’s and not another condition.
-
Biomarker Confirmation: Undergoing a PET scan or lumbar puncture to prove the presence of amyloid plaques in the brain.
-
Risk-Benefit Analysis: A detailed discussion regarding the 35% slowing of decline (as seen in trials) versus the risks of ARIA and the financial commitment of monthly infusions.
-
Exclusion Criteria: It is important to note that donanemab is not recommended for those with moderate to advanced dementia, nor is it a preventive measure for those without a confirmed diagnosis.
Looking Ahead
The launch of donanemab marks the beginning of a new era in Indian geriatric medicine. While it brings hope of “buying time” for those in the early stages of memory loss, its success will depend on more than just the science.
Transparent reporting of real-world outcomes in Indian patients, the development of clearer clinical guidelines, and a national dialogue on the affordability of breakthrough medicines will be essential to ensure that this scientific advancement translates into a meaningful public health benefit.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Journal & News Citations:
-
Reuters. “Eli Lilly launches Alzheimer’s drug Donanemab in India.” Published May 13, 2026.
